Danvatirsen and Venetoclax in Relapsed/Refractory MDS & AML
Phase 1
38
about 5.9 years
18+
2 sites in NY, TX
What this study is about
Researchers are testing the safety and effectiveness of Danvatirsen alone, followed by Danvatirsen combined with Venetoclax, in people whose leukemia (MDS or AML) has returned after treatment or hasn't responded to previous treatments. The trial will last for about 2 years.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Danvatirsen
- 2.Take Danvatirsen + Venetoclax
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
venetoclax
oral
Primary: Response to Therapy as determined by Overall Response Rate
Secondary: Duration of Response, Event-free survival, Overall Survival
Oncology